Cepheid (CPHD) 53.14 $CPHD
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 4:35PM CDT
MXIM: 35.00 (-0.19), AWAY: 32.27 (+0.76), GHL: 42.42 (-0.33), HBHC: 30.03 (+0.25), HWAY: 18.99 (-0.08), DV: 36.49 (+0.22), RGA: 93.16 (+0.14), FET: 21.65 (+0.74), GOOG: 539.36 (+5.39), COF: 81.76 (+0.23), FII: 34.50 (+0.44), MSFT: 42.99 (+0.36), BLDR: 13.00 (-0.09), EFII: 42.55 (+0.56), BCR: 175.09 (+0.24), LSTR: 65.26 (+0.57), ETH: 25.96 (+0.16), QDEL: 23.80 (+0.64), RSG: 39.75 (+0.16), HUBG: 37.84 (+0.04), BGS: 29.77 (-0.18), DGII: 9.40 (+0.11), PFG: 51.73 (+0.73), CPHD: 53.14 (-0.78), NTGR: 33.15 (+0.57), FSL: 41.53 (+0.49), ALTR: 42.78 (-0.46), CB: 99.30 (-0.44), N: 95.42 (+1.53), MTSN: 3.73 (+0.07), JNPR: 24.39 (+0.22), MXWL: 6.94 (-0.13), FR: 20.19 (-0.10), GIMO: 23.51 (+0.29), ELY: 9.83 (-0.23), P: 17.51 (+0.28), S: 5.08 (+0.10), RMD: 73.28 (+0.17), BJRI: 50.54 (-1.00), PEB: 45.45 (-0.08), FICO: 92.00 (-0.15), ETFC: 28.60 (+1.07), HBI: 34.12 (+0.23), CBI: 49.62 (-1.62), AMZN: 389.80 (-1.38), ALGN: 55.94 (-0.21), ACTG: 9.83 (-0.08), HA: 22.02 (-0.20), KN: 21.27 (-0.24), NEM: 22.77 (-0.74), MSCC: 35.98 (-0.16), CYN: 93.19 (+0.06), CVTI: 34.35 (-0.01), RHI: 59.59 (+0.30), QLIK: 33.68 (+0.31), MKTO: 28.84 (+0.98), BAS: 7.88 (+0.07), KLAC: 60.30 (+0.96), MMSI: 18.79 (+0.45)
Intuitive Surgical Q1 Earnings, Revenues Miss; Shares Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:25AM CDT
Following the earnings announcement, shares of Intuitive Surgical Inc. (ISRG) tumbled nearly 3.9% or $21.23 in after-hours trading to close at $525.50.
ISRG: 516.93 (-29.80), ABMD: 69.31 (-0.40), INGN: 36.39 (-0.04), CPHD: 53.14 (-0.78)
Cepheid's (CPHD) Xpert HIV-1 Qual Test Gets CE-IVD Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 3:13PM CDT
Cepheid recently received CE-IVD approval (under the European Directive on In Vitro Diagnostic Medical Devices) for its Xpert HIV-1 Qual.
ABMD: 69.31 (-0.40), CPHD: 53.14 (-0.78), LMNX: 16.34 (-0.01), ELMD: 2.41 (+0.04)
Cepheid and FIND Announce European Approval of Xpert HIV-1 Qual
PR Newswire - Thu Apr 16, 6:00AM CDT
Cepheid (Nasdaq: CPHD) and FIND today announced that Xpert® HIV-1 Qual, a qualitative 90-minute molecular HIV test, has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on the Cepheid GeneXpert® System, the world's leading molecular diagnostic platform with over 8,000 systems deployed globally in both developed and emerging market countries.
CPHD: 53.14 (-0.78)
Cepheid Announces European Approval of Xpert HCV Viral Load
PR Newswire - Wed Apr 15, 6:00AM CDT
Cepheid (NASDAQ: CPHD) today announced that Xpert® HCV Viral Load, a quantitative test that provides on-demand molecular testing for confirmation of infection and monitoring of Hepatitis C virus (HCV), has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on the Cepheid GeneXpert® System, the world's leading molecular diagnostic platform with over 8,000 systems deployed globally in both developed and emerging market countries.
CPHD: 53.14 (-0.78)
qPCR and dPCR Instrumentation Market: Educational/Research, Testing Laboratories, Pharmaceuticals - Global Strategic Business Report
M2 - Tue Apr 14, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tg6qrs/qpcr_and_dpcr) has announced the addition of the "qPCR and dPCR Instrumentation - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for qPCR and dPCR Instrumentation in US$ Thousands by the following Product Segments: qPCR (quantitative Polymerase Chain Reaction), and dPCR (digital Polymerase Chain Reaction). Also, the report analyzes the following End-Uses: Educational/Research, Testing Laboratories, Pharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a four-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 41 companies including many key and niche players such as: - Agilent Technologies, Inc. (US) - Becton, Dickinson and Company (US) - BioFire Diagnostics, Inc. (US) - Bio-Rad Laboratories, Inc. (US) - Cepheid (US) - Eppendorf AG (Germany) - Exiqon A/S (Denmark) - F. Hoffmann-La Roche Ltd. (Switzerland) - Fluidigm Corporation (US) - Illumina, Inc. (US) - Promega Corporation (US) - RainDance Technologies, Inc. (US) - QIAGEN N.V. (Netherlands) - Takara Bio, Inc. (Japan) - Thermo Fisher Scientific Inc. (US) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS, MARKET TRENDS & ISSUES 3. COMPETITION 4. END-USE MARKET ANALYSIS 5. PRODUCT OVERVIEW 6. INSIGHT INTO GLOBAL SPENDING ON LIFE SCIENCES RESEARCH 7. PRODUCT INNOVATIONS/INTRODUCTIONS 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 41 (including Divisions/Subsidiaries (44) - The United States (26) - Canada (1) - Japan (1) - Europe (15) - Germany (5) - The United Kingdom (2) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (1) For more information visit http://www.researchandmarkets.com/research/tg...r_and_dpcr
FLDM: 43.04 (-1.36), A: 42.71 (-0.18), CPHD: 53.14 (-0.78), ILMN: 190.04 (-9.27), QGEN: 24.93 (-0.15)
Is Great Basin Scientific Just Another Pump And Dump?
The GeoTeam - Seeking Alpha - Wed Apr 08, 12:57PM CDT
GeoInvesting is currently short Great Basic Scientific (NASDAQ: GBSN ), a rapid diagnostic medical test (Nucleic Acid Assay Testing) firm. We first alerted GeoInvesting premium members that we identified red flags associated with GBSN on March 30,...
GNMK: 10.51 (-0.22), GBSN: 4.98 (+1.44), BDX: 144.33 (-1.24), VIVO: 18.89 (+0.01), QDEL: 23.80 (+0.64), CPHD: 53.14 (-0.78), TTOO: 16.10 (-1.15), QGEN: 24.93 (-0.15), HOLX: 33.26 (-0.07), NSPH: 4.05 (+0.10)
CEPHEID
at Investor's Business Daily - Tue Apr 07, 5:52PM CDT
CEPHEID (CPHD), a molecular diagnostics company, named Ilan Daskal as CFO. Shares rose 1.5% to 56.72.
CPHD: 53.14 (-0.78)
Cepheid names new CFO; shares rise
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 3:54PM CDT
CPHD: 53.14 (-0.78)
Cepheid Welcomes Executive Vice President And Chief Financial Officer
PR Newswire - Tue Apr 07, 3:07PM CDT
Cepheid (Nasdaq: CPHD) today announced that it has appointed Mr. Ilan Daskal to the position of Executive Vice President and Chief Financial Officer, effective April 9, 2015. Mr. Daskal will assume responsibility for worldwide finance operations, information technology, and investor relations.
IRF: 39.98 (-0.01), CPHD: 53.14 (-0.78)
Cepheid Schedules 2015 First Quarter Results Announcement And Webcast
PR Newswire - Tue Apr 07, 3:05PM CDT
Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its 2015 first quarter ended March 31, 2015 on Thursday, April 23, 2015, after the close of the market.
CPHD: 53.14 (-0.78)
3 Hale & Hearty Stocks for World Health Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 1:31PM CDT
For investors who seek a greener portfolio, the health of these stocks should be appealing.
AZN: 73.35 (+0.65), CPHD: 53.14 (-0.78), GSK: 46.57 (-0.67), TSN: 38.18 (+0.07), MSFT: 42.99 (+0.36), AAPL: 128.62 (+1.71)
Top 100 North America Medical Devices/Technology/Supplies Companies 2015
M2 - Tue Apr 07, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxbbv3/north_america) has announced the addition of the "North America Medical Devices/Technology/Supplies 100: An Industry Report" report to their offering. Medical technology aims to improve the quality of healthcare provided. Recent advances in this industry globally are focusing on cost reduction, less-invasive treatment options, and reduction in hospital stays and rehabilitation process. The medical device industry is highly fragmented, and North America dominates with 46% of the global market. The North American medical technology market is expected to grow 6.4% annually through 2017. The North American healthcare information technology market is also forecast to grow at a compound annual growth rate of 7.4 percent to reach $31.3 billion by 2017 from $21.9 billion in 2012 due to the increasing demand for clinical information technology, and administrative solutions and services. Report Highlights: - Leading 100 medical devices/technology/supplies companies of North America - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances among North American medical devices/technology/supplies companies - International presence of North American medical devices/technology/supplies companies - R&D activities by North American medical devices/technology/supplies companies Key Topics Covered: 1. Rankings of North American Medical Devices/Technology/Supplies Companies 2. Stock Market Performance over 5 Years. Leading 25 North American Medical Devices/Technology/Supplies Companies 3. Key News of North American Medical Devices/Technology/Supplies Companies for Year 2014 4. Important Alliances among North American Medical Devices/Technology/Supplies Companies 5. International Presence of North American Medical Devices/Technology/Supplies Companies 6. Research and Development Activities by North American Medical Devices/Technology/Supplies Companies 7. Mergers and Acquisitions among North American Medical Devices/Technology/Supplies Companies Companies Mentioned - Partial List - 3M Company (United States) - Abaxis Inc (United States) - Abiomed, Inc. (United States) - Accuray Inc (United States) - Acme United Corporation (United States) - Affymetrix, Inc. (United States) - Align Technology, Inc. (United States) - American Science and Engineering, Inc. (United States) - Angiodynamics, Inc. (United States) - Atrion Corporation (United States) - Baxter International Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Boston Scientific Corporation (United States) - Bruker Corporation (United States) - C R Bard Inc (United States) - Cantel Medical Corp. (United States) - Carefusion Corporation (United States) - Cepheid (United States) - Coherent Incorporated (United States) For more information visit http://www.researchandmarkets.com/research/dx...th_america
BSX: 18.41 (+0.10), MMM: 164.67 (+0.67), ACU: 18.93 (-0.07), ALGN: 55.94 (-0.21), ABAX: 63.25 (-0.09), BAX: 70.38 (+0.33), CPHD: 53.14 (-0.78), COHR: 66.80 (-0.18), ASEI: 49.27 (+0.35), ARAY: 9.00 (unch), CMN: 48.33 (+0.23), AFFX: 12.57 (-0.13)
Sell Great Basin Scientific Inc., Penny Stock Newsletter Pumps Don't End Well
Big Banks - at Seeking Alpha - Mon Apr 06, 2:31PM CDT
GNMK: 10.51 (-0.22), GBSN: 4.98 (+1.44), RCAP: 8.49 (-0.08), QDEL: 23.80 (+0.64), CPHD: 53.14 (-0.78), RTGN: 3.67 (-0.27)
Cepheid Ships Record Xpert MTB/RIF to Mark World TB Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 1:30PM CDT
Cepheid (CPHD) believes that its Xpert MTB/RIF test has brought in a revolution in the field of digital disease detection.
ABMD: 69.31 (-0.40), INGN: 36.39 (-0.04), EW: 140.87 (+0.39), CPHD: 53.14 (-0.78)
Cepheid's Xpert Ebola Gets FDA's Nod for Emergency Use - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 10:50AM CDT
Cepheid (CPHD) expects to deliver 10,000 Xpert Ebola test kits for field testing and potential training deployment later in the first quarter of 2015.
ABMD: 69.31 (-0.40), INGN: 36.39 (-0.04), EW: 140.87 (+0.39), CPHD: 53.14 (-0.78)
Cepheid Receives Emergency Use Authorization from FDA for Xpert Ebola Diagnostic Test
PR Newswire - Tue Mar 24, 3:05PM CDT
Cepheid (Nasdaq: CPHD) today announced it has received Emergency Use Authorization from the U.S. Food & Drug Administration (FDA) for Xpert® Ebola, a molecular diagnostic test for Ebola Zaire Virus that delivers results in less than two hours. The test runs on the Cepheid GeneXpert® Systems, the world's leading molecular diagnostic platform with over 8,000 systems deployed globally in both developed and emerging market countries.
CPHD: 53.14 (-0.78)
Stocks to Cure What Ails on World TB Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 24, 1:26PM CDT
Grab These Stocks on World Tuberculosis Day.
JNJ: 100.43 (+0.13), AZN: 73.35 (+0.65), CPHD: 53.14 (-0.78), GSK: 46.57 (-0.67), QGEN: 24.93 (-0.15)
On World TB Day 2015 Cepheid and NHLS Commemorate Global Shipment of the 10 Millionth Xpert MTB/RIF Test Cartridge
PR Newswire - Tue Mar 24, 6:00AM CDT
Cepheid (Nasdaq: CPHD) and the National Health Laboratory Service (NHLS) in South Africa today recognized World TB Day 2015 by commemorating the global shipment of the 10 millionth Xpert MTB/RIF cartridge -- which was received by Helen Joseph Hospital Laboratory in Johannesburg, South Africa. The Xpert MTB/RIF test runs on Cepheid's GeneXpert® System, the world's leading molecular diagnostic platform with over 8,000 systems deployed globally in both developed and emerging market countries.
CPHD: 53.14 (-0.78)
Emerging IVD and Molecular Market Assessment in South Africa
M2 - Tue Mar 10, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/99dvpq/emerging_ivd_and) has announced the addition of the "Emerging IVD and Molecular Market Assessment in South Africa" report to their offering. Qualitative and quantitative assessment to provide accurate and detailed information for the Emerging IVD market from end users and KOL including: - An overview of the Infectious Disease Diagnostics laboratory market along with associated Microbiology, Immunoassay and Hematology methods. - In-depth information on test volumes, platforms and reagents for 32 tests Emerging markets are large and fragmented. Molecular testing is not frequently found so a systematic screening would not be effective. We have run the following research approach: Step 1: High Level Market Understanding Collection of market parameters relevant to the molecular IVD market based on secondary research including official programs, national and international documents and statistics. Step 2: Qualitative In Depth Interviews with KOL and Molecular Labs In depth interviews per country with key opinion leaders and high level professionals with insight in the present status of molecular diagnostics as well as information about future decisions & development e.g. large hospitals or private labs running molecular tests. Step 3: Market data by test type. Quantitative Interviews with molecular Labs Data was collected focusing on the following topics for 32 Infectious Disease tests (Adenovirus, CMV, Dengue, Enterovirus, EBV VL, HBV resistance, HBV VL, HCV genotyping, HCV qual., HCV VL, HIV genotyping, HIV qual., HIV VL, HPV qual., HPV genotyping, HSV 1 & 2, Influenza AB, Norovirus, RSV, VZV, cDiff, CT, CT/NG GAS, GBS, MRSA, MTB, NG, VRE, Chagas / Trypanosomiasis, Leishmaniasis, Malaria. - Test performance: test volumes per technologies used (molecular & microbiology) - Type of instruments & reagents used with manufacturer and model names - Specimen types for HSV, MRSA, CT/NG tests - Future trends per test Companies Mentioned - Roche Diagnostics - Life Technologies - Abbott - Bio-Rad - bioM?rieux - Cepheid - Analytik Jena - Qiagen - Siemens - Agilent - Thermo Scientific - Luminex - Hologic Hain Liefscience For more information visit http://www.researchandmarkets.com/research/99...ng_ivd_and
CPHD: 53.14 (-0.78), HOLX: 33.26 (-0.07)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 4:35PM CDT
MXIM: 35.00 (-0.19), AWAY: 32.27 (+0.76), GHL: 42.42 (-0.33), HBHC: 30.03 (+0.25), HWAY: 18.99 (-0.08), DV: 36.49 (+0.22), RGA: 93.16 (+0.14), FET: 21.65 (+0.74), GOOG: 539.36 (+5.39), COF: 81.76 (+0.23), FII: 34.50 (+0.44), MSFT: 42.99 (+0.36), BLDR: 13.00 (-0.09), EFII: 42.55 (+0.56), BCR: 175.09 (+0.24), LSTR: 65.26 (+0.57), ETH: 25.96 (+0.16), QDEL: 23.80 (+0.64), RSG: 39.75 (+0.16), HUBG: 37.84 (+0.04), BGS: 29.77 (-0.18), DGII: 9.40 (+0.11), PFG: 51.73 (+0.73), CPHD: 53.14 (-0.78), NTGR: 33.15 (+0.57), FSL: 41.53 (+0.49), ALTR: 42.78 (-0.46), CB: 99.30 (-0.44), N: 95.42 (+1.53), MTSN: 3.73 (+0.07), JNPR: 24.39 (+0.22), MXWL: 6.94 (-0.13), FR: 20.19 (-0.10), GIMO: 23.51 (+0.29), ELY: 9.83 (-0.23), P: 17.51 (+0.28), S: 5.08 (+0.10), RMD: 73.28 (+0.17), BJRI: 50.54 (-1.00), PEB: 45.45 (-0.08), FICO: 92.00 (-0.15), ETFC: 28.60 (+1.07), HBI: 34.12 (+0.23), CBI: 49.62 (-1.62), AMZN: 389.80 (-1.38), ALGN: 55.94 (-0.21), ACTG: 9.83 (-0.08), HA: 22.02 (-0.20), KN: 21.27 (-0.24), NEM: 22.77 (-0.74), MSCC: 35.98 (-0.16), CYN: 93.19 (+0.06), CVTI: 34.35 (-0.01), RHI: 59.59 (+0.30), QLIK: 33.68 (+0.31), MKTO: 28.84 (+0.98), BAS: 7.88 (+0.07), KLAC: 60.30 (+0.96), MMSI: 18.79 (+0.45)
Intuitive Surgical Q1 Earnings, Revenues Miss; Shares Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:25AM CDT
Following the earnings announcement, shares of Intuitive Surgical Inc. (ISRG) tumbled nearly 3.9% or $21.23 in after-hours trading to close at $525.50.
ISRG: 516.93 (-29.80), ABMD: 69.31 (-0.40), INGN: 36.39 (-0.04), CPHD: 53.14 (-0.78)
Cepheid's (CPHD) Xpert HIV-1 Qual Test Gets CE-IVD Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 3:13PM CDT
Cepheid recently received CE-IVD approval (under the European Directive on In Vitro Diagnostic Medical Devices) for its Xpert HIV-1 Qual.
ABMD: 69.31 (-0.40), CPHD: 53.14 (-0.78), LMNX: 16.34 (-0.01), ELMD: 2.41 (+0.04)
Cepheid and FIND Announce European Approval of Xpert HIV-1 Qual
PR Newswire - Thu Apr 16, 6:00AM CDT
Cepheid (Nasdaq: CPHD) and FIND today announced that Xpert® HIV-1 Qual, a qualitative 90-minute molecular HIV test, has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on the Cepheid GeneXpert® System, the world's leading molecular diagnostic platform with over 8,000 systems deployed globally in both developed and emerging market countries.
CPHD: 53.14 (-0.78)
Cepheid Announces European Approval of Xpert HCV Viral Load
PR Newswire - Wed Apr 15, 6:00AM CDT
Cepheid (NASDAQ: CPHD) today announced that Xpert® HCV Viral Load, a quantitative test that provides on-demand molecular testing for confirmation of infection and monitoring of Hepatitis C virus (HCV), has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on the Cepheid GeneXpert® System, the world's leading molecular diagnostic platform with over 8,000 systems deployed globally in both developed and emerging market countries.
CPHD: 53.14 (-0.78)
qPCR and dPCR Instrumentation Market: Educational/Research, Testing Laboratories, Pharmaceuticals - Global Strategic Business Report
M2 - Tue Apr 14, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tg6qrs/qpcr_and_dpcr) has announced the addition of the "qPCR and dPCR Instrumentation - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for qPCR and dPCR Instrumentation in US$ Thousands by the following Product Segments: qPCR (quantitative Polymerase Chain Reaction), and dPCR (digital Polymerase Chain Reaction). Also, the report analyzes the following End-Uses: Educational/Research, Testing Laboratories, Pharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a four-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 41 companies including many key and niche players such as: - Agilent Technologies, Inc. (US) - Becton, Dickinson and Company (US) - BioFire Diagnostics, Inc. (US) - Bio-Rad Laboratories, Inc. (US) - Cepheid (US) - Eppendorf AG (Germany) - Exiqon A/S (Denmark) - F. Hoffmann-La Roche Ltd. (Switzerland) - Fluidigm Corporation (US) - Illumina, Inc. (US) - Promega Corporation (US) - RainDance Technologies, Inc. (US) - QIAGEN N.V. (Netherlands) - Takara Bio, Inc. (Japan) - Thermo Fisher Scientific Inc. (US) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS, MARKET TRENDS & ISSUES 3. COMPETITION 4. END-USE MARKET ANALYSIS 5. PRODUCT OVERVIEW 6. INSIGHT INTO GLOBAL SPENDING ON LIFE SCIENCES RESEARCH 7. PRODUCT INNOVATIONS/INTRODUCTIONS 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 41 (including Divisions/Subsidiaries (44) - The United States (26) - Canada (1) - Japan (1) - Europe (15) - Germany (5) - The United Kingdom (2) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (1) For more information visit http://www.researchandmarkets.com/research/tg...r_and_dpcr
FLDM: 43.04 (-1.36), A: 42.71 (-0.18), CPHD: 53.14 (-0.78), ILMN: 190.04 (-9.27), QGEN: 24.93 (-0.15)
Is Great Basin Scientific Just Another Pump And Dump?
The GeoTeam - Seeking Alpha - Wed Apr 08, 12:57PM CDT
GeoInvesting is currently short Great Basic Scientific (NASDAQ: GBSN ), a rapid diagnostic medical test (Nucleic Acid Assay Testing) firm. We first alerted GeoInvesting premium members that we identified red flags associated with GBSN on March 30,...
GNMK: 10.51 (-0.22), GBSN: 4.98 (+1.44), BDX: 144.33 (-1.24), VIVO: 18.89 (+0.01), QDEL: 23.80 (+0.64), CPHD: 53.14 (-0.78), TTOO: 16.10 (-1.15), QGEN: 24.93 (-0.15), HOLX: 33.26 (-0.07), NSPH: 4.05 (+0.10)
CEPHEID
at Investor's Business Daily - Tue Apr 07, 5:52PM CDT
CEPHEID (CPHD), a molecular diagnostics company, named Ilan Daskal as CFO. Shares rose 1.5% to 56.72.
CPHD: 53.14 (-0.78)
Cepheid names new CFO; shares rise
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 3:54PM CDT
CPHD: 53.14 (-0.78)
Cepheid Welcomes Executive Vice President And Chief Financial Officer
PR Newswire - Tue Apr 07, 3:07PM CDT
Cepheid (Nasdaq: CPHD) today announced that it has appointed Mr. Ilan Daskal to the position of Executive Vice President and Chief Financial Officer, effective April 9, 2015. Mr. Daskal will assume responsibility for worldwide finance operations, information technology, and investor relations.
IRF: 39.98 (-0.01), CPHD: 53.14 (-0.78)
Cepheid Schedules 2015 First Quarter Results Announcement And Webcast
PR Newswire - Tue Apr 07, 3:05PM CDT
Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its 2015 first quarter ended March 31, 2015 on Thursday, April 23, 2015, after the close of the market.
CPHD: 53.14 (-0.78)
3 Hale & Hearty Stocks for World Health Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 1:31PM CDT
For investors who seek a greener portfolio, the health of these stocks should be appealing.
AZN: 73.35 (+0.65), CPHD: 53.14 (-0.78), GSK: 46.57 (-0.67), TSN: 38.18 (+0.07), MSFT: 42.99 (+0.36), AAPL: 128.62 (+1.71)
Top 100 North America Medical Devices/Technology/Supplies Companies 2015
M2 - Tue Apr 07, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxbbv3/north_america) has announced the addition of the "North America Medical Devices/Technology/Supplies 100: An Industry Report" report to their offering. Medical technology aims to improve the quality of healthcare provided. Recent advances in this industry globally are focusing on cost reduction, less-invasive treatment options, and reduction in hospital stays and rehabilitation process. The medical device industry is highly fragmented, and North America dominates with 46% of the global market. The North American medical technology market is expected to grow 6.4% annually through 2017. The North American healthcare information technology market is also forecast to grow at a compound annual growth rate of 7.4 percent to reach $31.3 billion by 2017 from $21.9 billion in 2012 due to the increasing demand for clinical information technology, and administrative solutions and services. Report Highlights: - Leading 100 medical devices/technology/supplies companies of North America - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances among North American medical devices/technology/supplies companies - International presence of North American medical devices/technology/supplies companies - R&D activities by North American medical devices/technology/supplies companies Key Topics Covered: 1. Rankings of North American Medical Devices/Technology/Supplies Companies 2. Stock Market Performance over 5 Years. Leading 25 North American Medical Devices/Technology/Supplies Companies 3. Key News of North American Medical Devices/Technology/Supplies Companies for Year 2014 4. Important Alliances among North American Medical Devices/Technology/Supplies Companies 5. International Presence of North American Medical Devices/Technology/Supplies Companies 6. Research and Development Activities by North American Medical Devices/Technology/Supplies Companies 7. Mergers and Acquisitions among North American Medical Devices/Technology/Supplies Companies Companies Mentioned - Partial List - 3M Company (United States) - Abaxis Inc (United States) - Abiomed, Inc. (United States) - Accuray Inc (United States) - Acme United Corporation (United States) - Affymetrix, Inc. (United States) - Align Technology, Inc. (United States) - American Science and Engineering, Inc. (United States) - Angiodynamics, Inc. (United States) - Atrion Corporation (United States) - Baxter International Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Boston Scientific Corporation (United States) - Bruker Corporation (United States) - C R Bard Inc (United States) - Cantel Medical Corp. (United States) - Carefusion Corporation (United States) - Cepheid (United States) - Coherent Incorporated (United States) For more information visit http://www.researchandmarkets.com/research/dx...th_america
BSX: 18.41 (+0.10), MMM: 164.67 (+0.67), ACU: 18.93 (-0.07), ALGN: 55.94 (-0.21), ABAX: 63.25 (-0.09), BAX: 70.38 (+0.33), CPHD: 53.14 (-0.78), COHR: 66.80 (-0.18), ASEI: 49.27 (+0.35), ARAY: 9.00 (unch), CMN: 48.33 (+0.23), AFFX: 12.57 (-0.13)
Sell Great Basin Scientific Inc., Penny Stock Newsletter Pumps Don't End Well
Big Banks - at Seeking Alpha - Mon Apr 06, 2:31PM CDT
GNMK: 10.51 (-0.22), GBSN: 4.98 (+1.44), RCAP: 8.49 (-0.08), QDEL: 23.80 (+0.64), CPHD: 53.14 (-0.78), RTGN: 3.67 (-0.27)
Cepheid Ships Record Xpert MTB/RIF to Mark World TB Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 1:30PM CDT
Cepheid (CPHD) believes that its Xpert MTB/RIF test has brought in a revolution in the field of digital disease detection.
ABMD: 69.31 (-0.40), INGN: 36.39 (-0.04), EW: 140.87 (+0.39), CPHD: 53.14 (-0.78)
Cepheid's Xpert Ebola Gets FDA's Nod for Emergency Use - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 10:50AM CDT
Cepheid (CPHD) expects to deliver 10,000 Xpert Ebola test kits for field testing and potential training deployment later in the first quarter of 2015.
ABMD: 69.31 (-0.40), INGN: 36.39 (-0.04), EW: 140.87 (+0.39), CPHD: 53.14 (-0.78)
Cepheid Receives Emergency Use Authorization from FDA for Xpert Ebola Diagnostic Test
PR Newswire - Tue Mar 24, 3:05PM CDT
Cepheid (Nasdaq: CPHD) today announced it has received Emergency Use Authorization from the U.S. Food & Drug Administration (FDA) for Xpert® Ebola, a molecular diagnostic test for Ebola Zaire Virus that delivers results in less than two hours. The test runs on the Cepheid GeneXpert® Systems, the world's leading molecular diagnostic platform with over 8,000 systems deployed globally in both developed and emerging market countries.
CPHD: 53.14 (-0.78)
Stocks to Cure What Ails on World TB Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 24, 1:26PM CDT
Grab These Stocks on World Tuberculosis Day.
JNJ: 100.43 (+0.13), AZN: 73.35 (+0.65), CPHD: 53.14 (-0.78), GSK: 46.57 (-0.67), QGEN: 24.93 (-0.15)
On World TB Day 2015 Cepheid and NHLS Commemorate Global Shipment of the 10 Millionth Xpert MTB/RIF Test Cartridge
PR Newswire - Tue Mar 24, 6:00AM CDT
Cepheid (Nasdaq: CPHD) and the National Health Laboratory Service (NHLS) in South Africa today recognized World TB Day 2015 by commemorating the global shipment of the 10 millionth Xpert MTB/RIF cartridge -- which was received by Helen Joseph Hospital Laboratory in Johannesburg, South Africa. The Xpert MTB/RIF test runs on Cepheid's GeneXpert® System, the world's leading molecular diagnostic platform with over 8,000 systems deployed globally in both developed and emerging market countries.
CPHD: 53.14 (-0.78)
Emerging IVD and Molecular Market Assessment in South Africa
M2 - Tue Mar 10, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/99dvpq/emerging_ivd_and) has announced the addition of the "Emerging IVD and Molecular Market Assessment in South Africa" report to their offering. Qualitative and quantitative assessment to provide accurate and detailed information for the Emerging IVD market from end users and KOL including: - An overview of the Infectious Disease Diagnostics laboratory market along with associated Microbiology, Immunoassay and Hematology methods. - In-depth information on test volumes, platforms and reagents for 32 tests Emerging markets are large and fragmented. Molecular testing is not frequently found so a systematic screening would not be effective. We have run the following research approach: Step 1: High Level Market Understanding Collection of market parameters relevant to the molecular IVD market based on secondary research including official programs, national and international documents and statistics. Step 2: Qualitative In Depth Interviews with KOL and Molecular Labs In depth interviews per country with key opinion leaders and high level professionals with insight in the present status of molecular diagnostics as well as information about future decisions & development e.g. large hospitals or private labs running molecular tests. Step 3: Market data by test type. Quantitative Interviews with molecular Labs Data was collected focusing on the following topics for 32 Infectious Disease tests (Adenovirus, CMV, Dengue, Enterovirus, EBV VL, HBV resistance, HBV VL, HCV genotyping, HCV qual., HCV VL, HIV genotyping, HIV qual., HIV VL, HPV qual., HPV genotyping, HSV 1 & 2, Influenza AB, Norovirus, RSV, VZV, cDiff, CT, CT/NG GAS, GBS, MRSA, MTB, NG, VRE, Chagas / Trypanosomiasis, Leishmaniasis, Malaria. - Test performance: test volumes per technologies used (molecular & microbiology) - Type of instruments & reagents used with manufacturer and model names - Specimen types for HSV, MRSA, CT/NG tests - Future trends per test Companies Mentioned - Roche Diagnostics - Life Technologies - Abbott - Bio-Rad - bioM?rieux - Cepheid - Analytik Jena - Qiagen - Siemens - Agilent - Thermo Scientific - Luminex - Hologic Hain Liefscience For more information visit http://www.researchandmarkets.com/research/99...ng_ivd_and
CPHD: 53.14 (-0.78), HOLX: 33.26 (-0.07)
